News | November 27, 2021
Fifty-five manufacturers selected for Pharma PLI sector
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Aurobindo has one of the most enduring generics ecosystems among peers
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Subscribe To Our Newsletter & Stay Updated
